Differentiation-state plasticity is a targetable resistance mechanism in basal-like breast cancer

Fast gapped-read alignment with Bowtie 2

Langmead, B., & Salzberg, S. L. (2012) · Nature Methods · doi:10.1038/nmeth.1923 · Cited by 56,400 · see citing works

Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles

Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625 · see citing works

Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources

Huang, D. W., Sherman, B. T., & Lempicki, R. A. (2009) · Nature Protocols · doi:10.1038/nprot.2008.211 · Cited by 35,890 · see citing works

Untitled work

(2008) · Journal of Machine Learning Research · Cited by 33,051 · see citing works

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989 · see citing works

Model-based Analysis of ChIP-Seq (MACS)

Zhang, Y., Liu, T., Meyer, C. A., Eeckhoute, J., Johnson, D. S., Bernstein, B. E., Nusbaum, C., Myers, R. M., Brown, M., Li, W., et al. (2008) · Genome Biology · doi:10.1186/gb-2008-9-9-r137 · Cited by 18,386 · see citing works

Differential expression analysis for sequence count data

Anders, S., & Huber, W. (2010) · Genome Biology · doi:10.1186/gb-2010-11-10-r106 · Cited by 15,581 · see citing works

Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer

Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,239 · see citing works

Comprehensive molecular portraits of human breast tumours

The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129 · see citing works

Drug combination studies and their synergy quantification using the Chou-Talalay method

Chou, T.-C. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1947 · Cited by 5,739 · see citing works

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

Lehmann, B. D., Bauer, J. A., Chen, X., Sanders, M. E., Chakravarthy, A. B., Shyr, Y., & Pietenpol, J. A. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45014 · Cited by 5,592 · see citing works

CellProfiler: image analysis software for identifying and quantifying cell phenotypes

Carpenter, A. E., Jones, T. R., Lamprecht, M. R., Clarke, C., Kang, I. H., Friman, O., Guertin, D. A., Chang, J. H., Lindquist, R. A., Moffat, J., et al. (2006) · Genome biology · doi:10.1186/gb-2006-7-10-r100 · Cited by 5,077 · see citing works

A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes

Neve, R. M., Chin, K., Fridlyand, J., Yeh, J., Baehner, F. L., Fevr, T., Clark, L., Bayani, N., Coppé, J., Tong, F. K., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.10.008 · Cited by 3,191 · see citing works

A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations

Sharma, S. V., Lee, D. Y., Li, B., Quinlan, M. P., Takahashi, F., Maheswaran, S., McDermott, U., Azizian, N., Zou, L., Fischbach, M. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.02.027 · Cited by 2,770 · see citing works

Genome-scale DNA methylation maps of pluripotent and differentiated cells

Meissner, A., Mikkelsen, T. S., Gu, H., Wernig, M., Hanna, J., Sivachenko, A., Zhang, X., Bernstein, B. E., Nusbaum, C., Jaffe, D. B., et al. (2008) · Nature · doi:10.1038/nature07107 · Cited by 2,536 · see citing works

An embryonic stem cell–like gene expression signature in poorly differentiated aggressive human tumors

Ben‐Porath, I., Thomson, M., Carey, V. J., Ge, R., Bell, G. W., Regev, A., & Weinberg, R. A. (2008) · Nature Genetics · doi:10.1038/ng.127 · Cited by 2,523 · see citing works

ARACNE: An Algorithm for the Reconstruction of Gene Regulatory Networks in a Mammalian Cellular Context

Margolin, A. A., Nemenman, I., Basso, K., Wiggins, C., Stolovitzky, G., Favera, R. D., & Califano, A. (2006) · BMC Bioinformatics · doi:10.1186/1471-2105-7-s1-s7 · Cited by 2,420 · see citing works

Identification of Selective Inhibitors of Cancer Stem Cells by High-Throughput Screening

Gupta, P. B., Önder, T. T., Jiang, G., Tao, K. X., Kuperwasser, C., Weinberg, R. A., & Lander, E. S. (2009) · Cell · doi:10.1016/j.cell.2009.06.034 · Cited by 2,393 · see citing works

Biomarkers for epithelial-mesenchymal transitions

Zeisberg, M., & Neilson, E. G. (2009) · Journal of Clinical Investigation · doi:10.1172/jci36183 · Cited by 2,299 · see citing works

ARACNE: An Algorithm for the Reconstruction of Gene Regulatory Networks in a Mammalian Cellular Context

Margolin, A. A., Nemenman, I. M., Basso, K., Wiggins, C. H., Stolovitzky, G. A., Favera, R. D., & Califano, A. (2006) · BMC Bioinformatics · doi:10.7916/d8g15zbp · Cited by 2,260 · see citing works

Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer

Prat, A., Parker, J. S., Karginova, O. A., Fan, C., Livasy, C., Herschkowitz, J. I., He, X., & Perou, C. M. (2010) · Breast Cancer Research · doi:10.1186/bcr2635 · Cited by 2,164 · see citing works

chromVAR: inferring transcription-factor-associated accessibility from single-cell epigenomic data

Schep, A. N., Wu, B., Buenrostro, J. D., & Greenleaf, W. J. (2017) · Nature Methods · doi:10.1038/nmeth.4401 · Cited by 1,680 · see citing works

Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers

kConFab, Lim, E., Vaillant, F., Wu, D., Forrest, N. C., Pal, B., Hart, A. H., Asselin-Labat, M.-L., Gyorki, D. E., Ward, T., et al. (2009) · Nature Medicine · doi:10.1038/nm.2000 · Cited by 1,492 · see citing works

Stochastic State Transitions Give Rise to Phenotypic Equilibrium in Populations of Cancer Cells

Gupta, P. B., Fillmore, C. M., Jiang, G., Shapira, S. D., Tao, K., Kuperwasser, C., & Lander, E. S. (2011) · Cell · doi:10.1016/j.cell.2011.07.026 · Cited by 1,475 · see citing works

Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features

Creighton, C. J., Li, X., Landis, M. D., Dixon, J. M., Neumeister, V. M., Sjolund, A. B., Rimm, D. L., Wong, H. H., Rodriguez, A. A., Herschkowitz, J. I., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905718106 · Cited by 1,414 · see citing works

Multiplex single-cell profiling of chromatin accessibility by combinatorial cellular indexing

Cusanovich, D. A., Daza, R., Adey, A., Pliner, H. A., Christiansen, L., Gunderson, K. L., Steemers, F. J., Trapnell, C., & Shendure, J. (2015) · Science · doi:10.1126/science.aab1601 · Cited by 1,248 · see citing works

Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state

Chaffer, C. L., Brueckmann, I., Scheel, C., Kaestli, A. J., Wiggins, P. A., Rodrigues, L. O., Brooks, M. W., Reinhardt, F., Su, Y., Polyák, K., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1102454108 · Cited by 1,137 · see citing works

Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC

Turke, A. B., Zejnullahu, K., Wu, Y.-L., Song, Y., Dias-Santagata, D., Lifshits, E., Toschi, L., Rogers, A., Mok, T., Sequist, L., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.11.022 · Cited by 1,059 · see citing works

Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors

Adalsteinsson, V. A., Ha, G., Freeman, S. S., Choudhury, A. D., Stover, D. G., Parsons, H. A., Gydush, G., Reed, S. C., Rotem, D., Rhoades, J., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00965-y · Cited by 1,034 · see citing works

Epithelial-Mesenchymal Transition in Cancer: Parallels Between Normal Development and Tumor Progression

Micalizzi, D. S., Farabaugh, S. M., & Ford, H. L. (2010) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-010-9178-9 · Cited by 979 · see citing works

Functional characterization of somatic mutations in cancer using network-based inference of protein activity

Alvarez, M. J., Shen, Y., Giorgi, F. M., Lachmann, A., Ding, B. B., Ye, B. H., & Califano, A. (2016) · Nature Genetics · doi:10.1038/ng.3593 · Cited by 966 · see citing works

Subtypes of Breast Cancer Show Preferential Site of Relapse

Smid, M., Wang, Y., Zhang, Y., Sieuwerts, A. M., Yu, J. X., Klijn, J. G. M., Foekens, J. A., & Martens, J. W. M. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5644 · Cited by 817 · see citing works

Chromatin state dynamics during blood formation

Lara-Astiaso, D., Weiner, A., Lorenzo-Vivas, E., Zaretsky, I., Jaitin, D. A., David, E., Keren-Shaul, H., Mildner, A., Winter, D., Jung, S., et al. (2014) · Science · doi:10.1126/science.1256271 · Cited by 776 · see citing works

Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer

Duncan, J. S., Whittle, M. C., Nakamura, K., Abell, A. N., Midland, A. A., Zawistowski, J. S., Johnson, N. L., Granger, D. A., Jordan, N. V., Darr, D. B., et al. (2012) · Cell · doi:10.1016/j.cell.2012.02.053 · Cited by 732 · see citing works

Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer

Shu, S., Lin, C. Y., He, H. H., Witwicki, R. M., Tabassum, D. P., Roberts, J. M., Janiszewska, M., Jin Huh, S., Liang, Y., Ryan, J., et al. (2016) · Nature · doi:10.1038/nature16508 · Cited by 632 · see citing works

Gene expression profiling of breast cell lines identifies potential new basal markers

Charafe‐Jauffret, E., Ginestier, C., Monville, F., Finetti, P., Adélaı̈de, J., Cervera, N., Fekairi, S., Xerri, L., Jacquemier, J. D., Birnbaum, D., et al. (2005) · Oncogene · doi:10.1038/sj.onc.1209254 · Cited by 571 · see citing works

Adaptive Chromatin Remodeling Drives Glioblastoma Stem Cell Plasticity and Drug Tolerance

Liau, B. B., Sievers, C., Donohue, L. K., Gillespie, S. M., Flavahan, W. A., Miller, T. E., Venteicher, A. S., Hebert, C. H., Carey, C. D., Rodig, S. J., et al. (2017) · Cell stem cell · doi:10.1016/j.stem.2016.11.003 · Cited by 535 · see citing works

Comparative Epigenomic Analysis of Murine and Human Adipogenesis

Mikkelsen, T. S., Zhao, X. D., Zhang, X., Wang, L., Gimble, J. M., Lander, E. S., & Rosen, E. D. (2010) · Cell · doi:10.1016/j.cell.2010.09.006 · Cited by 519 · see citing works

Studying clonal dynamics in response to cancer therapy using high-complexity barcoding

Bhang, H.-E. C., Ruddy, D. A., Krishnamurthy Radhakrishna, V., Caushi, J. X., Zhao, R., Hims, M. M., Singh, A. P., Kao, I., Rakiec, D., Shaw, P., et al. (2015) · Nature Medicine · doi:10.1038/nm.3841 · Cited by 507 · see citing works

A Renewable Tissue Resource of Phenotypically Stable, Biologically and Ethnically Diverse, Patient-Derived Human Breast Cancer Xenograft Models

Zhang, X., Claerhout, S., Prat, A., Dobrolecki, L. E., Petrovic, I., Lai, Q., Landis, M. D., Wiechmann, L., Schiff, R., Giuliano, M., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4081 · Cited by 483 · see citing works

Subtype and pathway specific responses to anticancer compounds in breast cancer

Heiser, L. M., Sadanandam, A., Kuo, W., Benz, S. C., Goldstein, T. C., Ng, S., Gibb, W. J., Wang, N. J., Ziyad, S., Tong, F. K., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1018854108 · Cited by 464 · see citing works

An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia

Knoechel, B., Roderick, J. E., Williamson, K. E., Zhu, J., Lohr, J. G., Cotton, M. J., Gillespie, S. M., Fernandez, D. E., Ku, M., Wang, H., et al. (2014) · Nature Genetics · doi:10.1038/ng.2913 · Cited by 369 · see citing works

An inhibitor of KDM5 demethylases reduces survival of drug-tolerant cancer cells

Vinogradova, M. V., Gehling, V. S., Gustafson, A. E., Arora, S., Tindell, C., WILSON, C. A., Williamson, K. E., Guler, G. D., Gangurde, P., Manieri, W., et al. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.2085 · Cited by 358 · see citing works

Developmental Fate and Cellular Maturity Encoded in Human Regulatory DNA Landscapes

Stergachis, A. B., Neph, S. J., Reynolds, A. P., Humbert, R., Miller, B. G., Paige, S. L., Vernot, B., Cheng, J. B., Thurman, R. E., Sandstrom, R. S., et al. (2013) · Cell · doi:10.1016/j.cell.2013.07.020 · Cited by 331 · see citing works

Phenotypic and functional characterisation of the luminal cell hierarchy of the mammary gland

Shehata, M., Teschendorff, A., Sharp, G., Novcic, N., Russell, I. A., Avril, S., Prater, M., Eirew, P., Caldas, C., Watson, C. J., et al. (2012) · Breast Cancer Research · doi:10.1186/bcr3334 · Cited by 306 · see citing works

Sequencing thousands of single-cell genomes with combinatorial indexing

Vitak, S. A., Torkenczy, K. A., Rosenkrantz, J. L., Fields, A. J., Christiansen, L., Wong, M. H., Carbone, L., Steemers, F. J., & Adey, A. (2017) · Nature Methods · doi:10.1038/nmeth.4154 · Cited by 294 · see citing works

Modeling precision treatment of breast cancer

Daemen, A., Griffith, O. L., Heiser, L. M., Wang, N. J., Enache, O. M., Sanborn, Z., Pepin, F., Durinck, S., Korkola, J. E., Griffith, M., et al. (2013) · Genome biology · doi:10.1186/gb-2013-14-10-r110 · Cited by 287 · see citing works

Inference of Tumor Evolution during Chemotherapy by Computational Modeling and In Situ Analysis of Genetic and Phenotypic Cellular Diversity

Almendro, V., Cheng, Y.-K., Randles, A. P., Itzkovitz, S., Marusyk, A., Ametller, E., González, X., Muñoz-Mateu, M., Russnes, H. G., Helland, Å., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2013.12.041 · Cited by 275 · see citing works

Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family Bromodomains

Stuhlmiller, T. J., Miller, S. M., Zawistowski, J. S., Nakamura, K., Beltrán, A. S., Duncan, J. S., Angus, S. P., Collins, K. A. L., Granger, D. A., Reuther, R. A., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.03.037 · Cited by 270 · see citing works

Temporally sequenced anticancer drugs overcome adaptive resistance by targeting a vulnerable chemotherapy-induced phenotypic transition

Goldman, A., Majumder, B., Dhawan, A., Ravi, S., Goldman, D., Kohandel, M., Majumder, P. K., & Sengupta, S. (2015) · Nature Communications · doi:10.1038/ncomms7139 · Cited by 260 · see citing works

Expression Profiling of Purified Normal Human Luminal and Myoepithelial Breast Cells

Jones, C., Mackay, A. G., Grigoriadis, A. E., Cossu, A., Reis-Filho, J. S., Fulford, L. G., Dexter, T., Davies, S., Bulmer, K., Ford, E., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2028 · Cited by 250 · see citing works

A Mammary Stem Cell Population Identified and Characterized in Late Embryogenesis Reveals Similarities to Human Breast Cancer

Spike, B. T., Engle, D. D., Lin, J., Cheung, S. K., La, J., & Wahl, G. M. (2012) · Cell stem cell · doi:10.1016/j.stem.2011.12.018 · Cited by 240 · see citing works

Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy

Στρατικόπουλος, Η., Dendy, M., Szabolcs, M. J., Khaykin, A. J., Lefèbvre, C., Zhou, M., & Parsons, R. E. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.05.006 · Cited by 234 · see citing works

Mapping the cellular and molecular heterogeneity of normal and malignant breast tissues and cultured cell lines

Keller, P. J., Lin, A. F., Arendt, L. M., Klebba, I., Jones, A. D., Rudnick, J. A., DiMeo, T. A., Gilmore, H. L., Jefferson, D. M., Graham, R. A., et al. (2010) · Breast Cancer Research · doi:10.1186/bcr2755 · Cited by 209 · see citing works

Characterization of cell lines derived from breast cancers and normal mammary tissues for the study of the intrinsic molecular subtypes

Prat, A., Karginova, O. A., Parker, J. S., Fan, C., He, X., Bixby, L. M., Harrell, J. C., Roman, E., Adamo, B., Troester, M. A., et al. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2743-3 · Cited by 202 · see citing works

Genome-wide Maps of Histone Modifications Unwind In Vivo Chromatin States of the Hair Follicle Lineage

Lien, W.-H., Guo, X., Polak, L., Lawton, L. N., Young, R. A., Zheng, D., & Fuchs, E. (2011) · Cell Stem Cell · doi:10.1016/j.stem.2011.07.015 · Cited by 199 · see citing works

Bromodomain 4 activation predicts breast cancer survival

Crawford, N. P. S., Alsarraj, J., Lukes, L., Walker, R. C., Officewala, J. S., Yang, H. H., Lee, M. P., Ozato, K., & Hunter, K. W. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710331105 · Cited by 190 · see citing works

Haplotype-resolved whole-genome sequencing by contiguity-preserving transposition and combinatorial indexing

Amini, S., Pushkarev, D., Christiansen, L., Kostem, E., Royce, T., Turk, C., Pignatelli, N., Adey, A., Kitzman, J. O., Vijayan, K., et al. (2014) · Nature Genetics · doi:10.1038/ng.3119 · Cited by 189 · see citing works

Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacologic Targeting of the P-TEFb Complex

Zawistowski, J. S., Bevill, S. M., Goulet, D. R., Stuhlmiller, T. J., Beltran, A. S., Olivares-Quintero, J. F., Singh, D., Sciaky, N., Parker, J. S., Rashid, N. U., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0653 · Cited by 180 · see citing works

Fra-1/AP-1 induces EMT in mammary epithelial cells by modulating Zeb1/2 and TGFβ expression

Bakiri, L., Macho‐Maschler, S., Custic, I., Niemiec, J., Guío-Carrión, A., Hasenfuss, S. C., Eger, A., Müller, M. M., Beug, H., & Wagner, E. F. (2014) · Cell Death and Differentiation · doi:10.1038/cdd.2014.157 · Cited by 161 · see citing works

Correcting for cancer genome size and tumour cell content enables better estimation of copy number alterations from next-generation sequence data

Gusnanto, A., Wood, H. M., Yudi Pawitan, Y., Rabbitts, P. H., & Berri, S. (2011) · Bioinformatics · doi:10.1093/bioinformatics/btr593 · Cited by 161 · see citing works

Kinase Pathway Dependence in Primary Human Leukemias Determined by Rapid Inhibitor Screening

Tyner, J. W., Yang, W. F., Bankhead, A., Fan, G., Fletcher, L. B., Bryant, J. A., Glover, J., Chang, B. H., Spurgeon, S. E. F., Fleming, W., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1906 · Cited by 150 · see citing works

Functional Analysis of the Transcription Repressor PLU-1/JARID1B

Scibetta, A. G., Santangelo, S., Coleman, J., Hall, D. M. S., Chaplin, T., Copier, J. P., Catchpole, S., Burchell, J., & Taylor-Papadimitriou, J. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.00274-07 · Cited by 143 · see citing works

The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma

Banelli, B., Carra, E., Barbieri, F., Würth, R., Parodi, F., Pattarozzi, A., Carosio, R., Forlani, A., Allemanni, G., Marubbi, D., et al. (2015) · Cell Cycle · doi:10.1080/15384101.2015.1090063 · Cited by 135 · see citing works

Role of myoepithelial cells in breast tumor progression

Pandey, P. R. (2009) · Frontiers in bioscience · doi:10.2741/3617 · Cited by 126 · see citing works

Analysis of Normal Human Mammary Epigenomes Reveals Cell-Specific Active Enhancer States and Associated Transcription Factor Networks

Pellacani, D., Bilenky, M., Kannan, N., Heravi‐Moussavi, A., Knapp, D. J. H. F., Gakkhar, S., Moksa, M., Carles, A., Moore, R. A., Mungall, A. J. J., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.10.058 · Cited by 114 · see citing works

Microenvironment-Mediated Mechanisms of Resistance to HER2 Inhibitors Differ between HER2+ Breast Cancer Subtypes

Watson, S. S., Dane, M. A., Chin, K., Tatárová, Z., Liu, M., Liby, T. A., Thompson, W., Smith, R. L., Nederlof, M. A., Bucher, E., et al. (2018) · Cell Systems · doi:10.1016/j.cels.2018.02.001 · Cited by 91 · see citing works

Spontaneous Epithelial-Mesenchymal Transition and Resistance to HER-2-Targeted Therapies in HER-2-Positive Luminal Breast Cancer

Lesniak, D. M., Sabri, S., Xu, Y., Graham, K., Bhatnagar, P. K., Suresh, M. R., & Abdulkarim, B. (2013) · PLoS ONE · doi:10.1371/journal.pone.0071987 · Cited by 70 · see citing works

Epigenetic and transcriptional determinants of the human breast

Gascard, P. D., Bilenky, M., Sigaroudinia, M., Zhao, J., Li, L., Carles, A., Delaney, A. D., Tam, A., Kamoh, B., Cho, S. H., et al. (2015) · Nature Communications · doi:10.1038/ncomms7351 · Cited by 69 · see citing works

Sequencing of breast cancer stem cell populations indicates a dynamic conversion between differentiation states in vivo

Klevebring, D., Rosin, G., Ma, R., Lindberg, J., Czene, K., Kere, J., Fredriksson, I., Bergh, J. C. S., & Hartman, J. (2014) · Breast Cancer Research · doi:10.1186/bcr3687 · Cited by 61 · see citing works

EZH2 promotes a bi-lineage identity in basal-like breast cancer cells

Granit, R. Z., Gabai, Y., Hadar, T., Karamansha, Y., Liberman, L., Waldhorn, I., Gat‐Viks, I., Regev, A., Maly, B., Darash‐Yahana, M., et al. (2012) · Oncogene · doi:10.1038/onc.2012.390 · Cited by 38 · see citing works

Luminal progenitor and fetal mammary stem cell expression features predict breast tumor response to neoadjuvant chemotherapy

Pfefferle, A. D., Spike, B. T., Wahl, G., & Perou, C. M. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-3262-6 · Cited by 30 · see citing works

Expression of GATA3 in MDA-MB-231 Triple-negative Breast Cancer Cells Induces a Growth Inhibitory Response to TGFß

Chu, I. M., Lai, W.-C. V., Aprelikova, O. N., Touny, L. H. E., Kouros‐Mehr, H., & Green, J. E. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061125 · Cited by 29 · see citing works

MicroRNA-182 drives colonization and macroscopic metastasis via targeting its suppressor SNAI1 in breast cancer

Zhan, Y., Li, X., Liang, X., Li, L., Cao, B., Wang, B., Ma, J., Ding, F., Wang, X., Pang, D., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.13542 · Cited by 22 · see citing works

A model of phenotypic state dynamics initiates a promising approach to control heterogeneous malignant cell populations

Chapman, M. P., Risom, T., Aswani, A. J., Dobbe, R., Sears, R. C., & Tomlin, C. J. (2016) · IEEE Conference on Decision and Control (CDC) · doi:10.1109/cdc.2016.7798634 · Cited by 14 · see citing works

Intratumor Heterogeneity: The Rosetta Stone of Therapy Resistance

Marusyk, A., Janiszewska, M., & Polyak, K. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.007 · Cited by 1,009 · see citing works

Colorectal Cancer Cells Enter a Diapause-like DTP State to Survive Chemotherapy

Rehman, S. K., Haynes, J., Collignon, E., Brown, K. R., Wang, Y., Nixon, A. M. L., Bruce, J. P., Wintersinger, J. A., Singh Mer, A., Lo, E. B. L., et al. (2021) · Cell · doi:10.1016/j.cell.2020.11.018 · Cited by 495 · see citing works

Expanding the coverage of regulons from high-confidence prior knowledge for accurate estimation of transcription factor activities

Müller‐Dott, S., Tsirvouli, E., Vázquez, M., Flores, R. O. R., Badia-i-Mompel, P., Fallegger, R., Türei, D., Lægreid, A., & Sáez-Rodríguez, J. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad841 · Cited by 404 · see citing works

Targeting Cancer Cell Dormancy

Recasens, A., & Munoz, L. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2018.12.004 · Cited by 356 · see citing works

Cancer cell plasticity during tumor progression, metastasis and response to therapy

Pérez-González, A., Bévant, K., & Blanpain, C. (2023) · Nature Cancer · doi:10.1038/s43018-023-00595-y · Cited by 353 · see citing works

Cancer overdiagnosis: a biological challenge and clinical dilemma

Srivastava, S., Koay, E. J., Borowsky, A. D., Marzo, A. M. D., Ghosh, S., Wagner, P. D., & Kramer, B. S. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0142-8 · Cited by 339 · see citing works

Bacterial Endotoxin Activates the Coagulation Cascade through Gasdermin D-Dependent Phosphatidylserine Exposure

Yang, X., Cheng, X., Tang, Y., Qiu, X., Wang, Y., Kang, H., Wu, J., Wang, Z., Liu, Y., Chen, F., et al. (2019) · Immunity · doi:10.1016/j.immuni.2019.11.005 · Cited by 329 · see citing works

Cancer cell heterogeneity and plasticity: A paradigm shift in glioblastoma

Yabo, Y. A., Niclou, S. P., & Golebiewska, A. (2021) · Neuro-Oncology · doi:10.1093/neuonc/noab269 · Cited by 315 · see citing works

Persistent Cancer Cells: The Deadly Survivors

Shen, S., Vagner, S., & Robert, C. (2020) · Cell · doi:10.1016/j.cell.2020.10.027 · Cited by 304 · see citing works

Resistance to neoadjuvant chemotherapy in triple-negative breast cancer mediated by a reversible drug-tolerant state

Echeverria, G. V., Ge, Z., Seth, S., Zhang, X., Jeter-Jones, S. L., Zhou, X., Cai, S., Tu, Y., McCoy, A., Peoples, M. D., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aav0936 · Cited by 307 · see citing works

Nanotechnology for Boosting Cancer Immunotherapy and Remodeling Tumor Microenvironment: The Horizons in Cancer Treatment

Gao, S., Yang, X., Xu, J., Qiu, N., & Zhai, G. (2021) · ACS Nano · doi:10.1021/acsnano.1c02103 · Cited by 240 · see citing works

Intratumoral Heterogeneity: More Than Just Mutations

Hinohara, K., & Polyák, K. (2019) · Trends in Cell Biology · doi:10.1016/j.tcb.2019.03.003 · Cited by 231 · see citing works

Bromodomain and extraterminal (BET) proteins: biological functions, diseases and targeted therapy

Wang, Z., Zhang, Z.-C., Wu, Y., Pi, Y., Lou, S., Liu, T., Lou, G., & Yang, C. Q. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01647-6 · Cited by 222 · see citing works

Mechanism of Drug Tolerant Persister Cancer Cells: The Landscape and Clinical Implication for Therapy

Mikubo, M., Inoue, Y., Liu, G., & Tsao, M. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.07.017 · Cited by 212 · see citing works

Cancer drug-tolerant persister cells: from biological questions to clinical opportunities

Russo, M., Chen, M., Mariella, E., Peng, H., Rehman, S. K., Sancho, E., Sogari, A., Toh, T. S., Balaban, N. Q., Batlle, E., et al. (2024) · Nature Reviews Cancer · doi:10.1038/s41568-024-00737-z · Cited by 210 · see citing works

Stem Cell Plasticity and Dormancy in the Development of Cancer Therapy Resistance

Angelis, M. L. D., Francescangeli, F., Torre, F. L., & Zeuner, A. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00626 · Cited by 203 · see citing works

Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer

Cabanos, H. F., & Hata, A. N. (2021) · Cancers · doi:10.3390/cancers13112666 · Cited by 189 · see citing works

Drug-tolerant persister cells in cancer: the cutting edges and future directions

Pu, Y., Li, L., Peng, H., Liu, L., Heymann, D., Robert, C., Vallette, F. M., & Shen, S. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00815-5 · Cited by 179 · see citing works

Breast Cancer Stem Cells as Drivers of Tumor Chemoresistance, Dormancy and Relapse: New Challenges and Therapeutic Opportunities

Angelis, M. L. D., Francescangeli, F., & Zeuner, A. (2019) · Cancers · doi:10.3390/cancers11101569 · Cited by 176 · see citing works

Heterogeneity within molecular subtypes of breast cancer

Turner, K. M., Yeo, S. K., Holm, T. M., Shaughnessy, E., & Guan, J. (2021) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00109.2021 · Cited by 160 · see citing works

Mission Possible: Advances in MYC Therapeutic Targeting in Cancer

Allen-Petersen, B. L., & Sears, R. C. (2019) · BioDrugs · doi:10.1007/s40259-019-00370-5 · Cited by 143 · see citing works

Drug-Tolerant Persister Cells in Cancer Therapy Resistance

Dhanyamraju, P. K., Schell, T. D., Amin, S., & Robertson, G. P. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-3844 · Cited by 145 · see citing works

Resistance to targeted therapies as a multifactorial, gradual adaptation to inhibitor specific selective pressures

Velde, R. V., Yoon, N., Marusyk, V., Durmaz, A., Dhawan, A., Miroshnychenko, D., Lozano‐Peral, D., Desai, B., Balynska, O. V., Poleszczuk, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16212-w · Cited by 135 · see citing works

Epithelial–Mesenchymal Transition Programs and Cancer Stem Cell Phenotypes: Mediators of Breast Cancer Therapy Resistance

Gooding, A. J., & Schiemann, W. P. (2020) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-20-0067 · Cited by 136 · see citing works

m6A RNA methylation-mediated HNF3γ reduction renders hepatocellular carcinoma dedifferentiation and sorafenib resistance

Zhou, T., Li, S., Xiang, D., Liu, J., Sun, W. C., Cui, X., Ning, B., Li, X., Cheng, Z., Jiang, W., et al. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00299-0 · Cited by 118 · see citing works

A mechanism for epithelial-mesenchymal heterogeneity in a population of cancer cells

Tripathi, S., Chakraborty, P., Levine, H., & Jolly, M. K. (2020) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1007619 · Cited by 112 · see citing works

Fighting Drug Resistance through the Targeting of Drug-Tolerant Persister Cells

De Conti, G., Dias, M. H., & Bernards, R. (2021) · Cancers · doi:10.3390/cancers13051118 · Cited by 111 · see citing works

The multiverse nature of epithelial to mesenchymal transition

Simeone, P., Trerotola, M., Franck, J., Cardon, T., Marchisio, M., Fournier, I., Salzet, M., Maffia, M., & Vergara, D. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.11.004 · Cited by 98 · see citing works

Hypoxia-driven intratumor heterogeneity and immune evasion

Terry, S., Engelsen, A. S. T., Buart, S., El‐Sayed, W., Venkatesh, G. H., & Chouaı̈b, S. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.07.004 · Cited by 100 · see citing works

New Insights Into the Role of Phenotypic Plasticity and EMT in Driving Cancer Progression

Bhatia, S., Wang, P., Toh, A. K. L., & Thompson, E. W. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.00071 · Cited by 94 · see citing works

Inhibition of NPC1L1 disrupts adaptive responses of drug‐tolerant persister cells to chemotherapy

Zhang, Z., Qin, S., Chen, Y., Zhou, L., Yang, M. X., Tang, Y., Zuo, J., Zhang, J., Mizokami, A., Nice, E. C., et al. (2022) · EMBO Molecular Medicine · doi:10.15252/emmm.202114903 · Cited by 90 · see citing works

Cancer stem cells in colorectal cancer: Signaling pathways involved in stemness and therapy resistance

Ebrahimi, N., Afshinpour, M., Fakhr, S. S., Kalkhoran, P. G., Shadman-Manesh, V., Adelian, S., Beiranvand, S., Rezaei‐Tazangi, F., Khorram, R., Hamblin, M. R., et al. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.103920 · Cited by 90 · see citing works

The Physics of Cellular Decision Making During Epithelial–Mesenchymal Transition

Tripathi, S., Levine, H., & Jolly, M. K. (2020) · Annual Review of Biophysics · doi:10.1146/annurev-biophys-121219-081557 · Cited by 88 · see citing works

Breast Cancer Heterogeneity and Response to Novel Therapeutics

Baliu‐Piqué, M., Pandiella, A., & Ocaña, A. (2020) · Cancers · doi:10.3390/cancers12113271 · Cited by 86 · see citing works

Untangling the web of intratumour heterogeneity

Li, Z., Seehawer, M., & Polyák, K. (2022) · Nature Cell Biology · doi:10.1038/s41556-022-00969-x · Cited by 81 · see citing works

A census of pathway maps in cancer systems biology

Kuenzi, B. M., & Ideker, T. (2020) · Nature reviews. Cancer · doi:10.1038/s41568-020-0240-7 · Cited by 79 · see citing works

Characteristics of pre-metastatic niche: the landscape of molecular and cellular pathways

Wang, H., Pan, J., Barsky, L., Jacob, J. C., Zheng, Y., Gao, C., Wang, S., Zhu, W., Sun, H., Lu, L., et al. (2021) · Molecular Biomedicine · doi:10.1186/s43556-020-00022-z · Cited by 77 · see citing works

Upregulation of lncRNA NIFK-AS1 in hepatocellular carcinoma by m6A methylation promotes disease progression and sorafenib resistance

Chen, Y., Xiang, D., Zhao, X., & Chu, X. (2021) · Human Cell · doi:10.1007/s13577-021-00587-z · Cited by 72 · see citing works

Dormancy, stemness, and therapy resistance: interconnected players in cancer evolution

Francescangeli, F., Angelis, M. L. D., Rossi, R., Cuccu, A., Giuliani, A., Maria, R. D., & Zeuner, A. (2023) · Cancer and Metastasis Reviews · doi:10.1007/s10555-023-10092-4 · Cited by 77 · see citing works

Archetype tasks link intratumoral heterogeneity to plasticity and cancer hallmarks in small cell lung cancer

Groves, S. M., Ildefonso, G. V., McAtee, C. O., Ozawa, P. M. M., Ireland, A. S., Stauffer, P. E., Wasdin, P. T., Huang, X., Qiao, Y., Lim, J. S., et al. (2022) · Cell Systems · doi:10.1016/j.cels.2022.07.006 · Cited by 64 · see citing works

Laboratory Models for Investigating Breast Cancer Therapy Resistance and Metastasis

Roarty, K. P., & Echeverria, G. V. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.645698 · Cited by 64 · see citing works

A cell cycle centric view of tumour dormancy

Weston, W. A., & Barr, A. R. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02401-z · Cited by 64 · see citing works

Breast cancer stem cells: A review of their characteristics and the agents that affect them

Shan, N. L., Shin, Y. S., Yang, G., Furmanski, P., & Suh, N. (2021) · Molecular Carcinogenesis · doi:10.1002/mc.23277 · Cited by 62 · see citing works

Effective targeting of breast cancer by the inhibition of P-glycoprotein mediated removal of toxic lipid peroxidation byproducts from drug tolerant persister cells

Szebényi, K., Füredi, A., Bajtai, E., Sama, S. N., Csiszar, A., Gombos, B., Szabó, P. T., Grusch, M., & Szakács, G. (2023) · Drug Resistance Updates · doi:10.1016/j.drup.2023.101007 · Cited by 59 · see citing works

Tumor Heterogeneity and Consequences for Bladder Cancer Treatment

Lavallee, E., Sfakianos, J., & Mulholland, D. (2021) · Cancers · doi:10.3390/cancers13215297 · Cited by 43 · see citing works

Drug-induced tolerant persisters in tumor: mechanism, vulnerability and perspective implication for clinical treatment

Liu, S., Jiang, A., Tang, F., Duan, M., & Li, B. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02323-9 · Cited by 53 · see citing works

Dynamic transcriptional reprogramming leads to immunotherapeutic vulnerabilities in myeloma

Frede, J., Anand, P., Sotudeh, N., Pinto, R. A., Nair, M. S., Stuart, H., Yee, A. J., Vijaykumar, T., Waldschmidt, J. M., Potdar, S. V., et al. (2021) · Nature Cell Biology · doi:10.1038/s41556-021-00766-y · Cited by 54 · see citing works

Pre-clinical validation of an RNA-based precision oncology platform for patient-therapy alignment in a diverse set of human malignancies resistant to standard treatments

Mundi, P. S., Dela Cruz, F. S., Grunn, A., Diolaiti, D., Mauguen, A., Rainey, A. R., Guillan, K. C., Siddiquee, A., You, D., Realubit, R., et al. (2021) · doi:10.1101/2021.10.03.462951 · Cited by 51 · see citing works

Deregulating MYC in a model of HER2+ breast cancer mimics human intertumoral heterogeneity

Risom, T., Wang, X., Liang, J. B., Zhang, X., Pelz, C., Campbell, L. G., Eng, J., Chin, K., Farrington, C. C., Narla, G., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci126390 · Cited by 48 · see citing works

Measuring and Modelling the Epithelial- Mesenchymal Hybrid State in Cancer: Clinical Implications

Jolly, M. K., Murphy, R. J., Bhatia, S., Whitfield, H. J., Redfern, A. D., Davis, M. J., & Thompson, E. W. (2021) · Cells Tissues Organs · doi:10.1159/000515289 · Cited by 46 · see citing works

Rewiring of mitochondrial metabolism in therapy-resistant cancers: permanent and plastic adaptations

Pendleton, K. E., Wang, K., & Echeverria, G. V. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1254313 · Cited by 41 · see citing works

OncoLoop: A Network-Based Precision Cancer Medicine Framework

Vasciaveo, A., Arriaga, J. M., de Almeida, F. N., Zou, M., Douglass, E. F., Picech, F., Shibata, M., Rodríguez-Calero, A., de Brot, S., Mitrofanova, A., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0342 · Cited by 38 · see citing works

Cell-Intrinsic Mechanisms of Drug Tolerance to Systemic Therapies in Cancer

Léonce, C., Saintigny, P., & Ortiz‐Cuaran, S. (2021) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-21-0038 · Cited by 37 · see citing works

Increased m6A modification of lncRNA DBH-AS1 suppresses pancreatic cancer growth and gemcitabine resistance via the miR-3163/USP44 axis

Ye, X., Wang, L., Han, C., Hu, H., Ni, C., Qiao, G., Ouyang, L., & Ni, J.-S. (2022) · Annals of Translational Medicine · doi:10.21037/atm-22-556 · Cited by 36 · see citing works

Engaging plasticity: Differentiation therapy in solid tumors

Bar-Hai, N., & Ishay-Ronen, D. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.944773 · Cited by 35 · see citing works

Research Progress of Plant-Derived Natural Products against Drug-Resistant Cancer

Liu, W., Wang, Y., Xia, L., & Li, J. (2024) · Nutrients · doi:10.3390/nu16060797 · Cited by 35 · see citing works

A prismatic view of the epigenetic-metabolic regulatory axis in breast cancer therapy resistance

Das, C., Bhattacharya, A., Adhikari, S., Mondal, A., Mondal, P., Adhikary, S., Roy, S., Ramos, K. S., Yadav, K. K., Tainer, J. A., et al. (2024) · Oncogene · doi:10.1038/s41388-024-03054-9 · Cited by 38 · see citing works

Cyclic Multiplexed-Immunofluorescence (cmIF), a Highly Multiplexed Method for Single-Cell Analysis

Eng, J. R., Thibault, G., Luoh, S., Gray, J. W., Chang, Y. H., & Chin, K. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9773-2_24 · Cited by 34 · see citing works

An in vitro model of tumor heterogeneity resolves genetic, epigenetic, and stochastic sources of cell state variability

Hayford, C. E., Tyson, D. R., Robbins, C. T., Frick, P. L., Quaranta, V., & Harris, L. A. (2021) · PLoS Biology · doi:10.1371/journal.pbio.3000797 · Cited by 36 · see citing works

Unraveling non-genetic heterogeneity in cancer with dynamical models and computational tools

Pillai, M., Hojel, E., Jolly, M. K., & Goyal, Y. (2023) · Nature Computational Science · doi:10.1038/s43588-023-00427-0 · Cited by 33 · see citing works

Metabolic adaptation towards glycolysis supports resistance to neoadjuvant chemotherapy in early triple negative breast cancers

Derouane, F., Desgres, M., Moroni, C., Ambroise, J., Berlière, M., Bockstal, M. V., Galant, C., van Marcke, C., Vara-Messler, M., Hutten, S. J., et al. (2024) · Breast Cancer Research · doi:10.1186/s13058-024-01788-8 · Cited by 33 · see citing works

Improving Cancer Drug Discovery by Studying Cancer across the Tree of Life

Somarelli, J. A., Boddy, A. M., Gardner, H. L., DeWitt, S. B., Tuohy, J. L., Megquier, K., Sheth, M. U., Hsu, S. D., Thorne, J. L., London, C. A., et al. (2019) · Molecular Biology and Evolution · doi:10.1093/molbev/msz254 · Cited by 30 · see citing works

Radiation induces an inflammatory response that results in STAT3-dependent changes in cellular plasticity and radioresistance of breast cancer stem-like cells

Arnold, K. M., Opdenaker, L. M., Flynn, N. J., Appeah, D. K., & Sims‐Mourtada, J. (2019) · International Journal of Radiation Biology · doi:10.1080/09553002.2020.1705423 · Cited by 30 · see citing works

Early Steps of Resistance to Targeted Therapies in Non-Small-Cell Lung Cancer

Delahaye, C., Figarol, S., Pradines, A., Favre, G., Mazières, J., & Calvayrac, O. (2022) · Cancers · doi:10.3390/cancers14112613 · Cited by 28 · see citing works

Targeting drug‐tolerant cells: A promising strategy for overcoming acquired drug resistance in cancer cells

Song, X.-H., Yang, L., Zheng, X., Zhu, Q., Liao, X.-L., Liu, K., Zhang, W., Peng, Q., Zhu, Y., Zhao, L.-Y., et al. (2023) · MedComm · doi:10.1002/mco2.342 · Cited by 26 · see citing works

RSK2: a promising therapeutic target for the treatment of triple-negative breast cancer

Huynh, M.-M., Jayanthan, A., Pambid, M. R., Los, G., & Dunn, S. E. (2019) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2020.1709824 · Cited by 28 · see citing works

Resistance to mesenchymal reprogramming sustains clonal propagation in metastatic breast cancer

Saini, M., Schmidleitner, L., Moreno, H. D., Donato, E., Falcone, M., Bartsch, J. M., Klein, C., Vogel, V., Würth, R., Pfarr, N., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112533 · Cited by 25 · see citing works

2-Hydroxyglutarate destabilizes chromatin regulatory landscape and lineage fidelity to promote cellular heterogeneity

Kusi, M., Zand, M., Lin, L., Chen, M., Lopez, A., Lin, C.-L., Wang, C., Lucio, N. L. L., Kirma, N. B., Ruan, J., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2021.110220 · Cited by 25 · see citing works

Morphodynamical cell state description via live-cell imaging trajectory embedding

Copperman, J., Gross, S. M., Chang, Y. H., Heiser, L. M., & Zuckerman, D. M. (2023) · Communications Biology · doi:10.1038/s42003-023-04837-8 · Cited by 25 · see citing works

Discrete-time MPC for switched systems with applications to biomedical problems

Anderson, A., González, A. H., Ferramosca, A., & Hernandez-Vargas, E. A. (2020) · Communications in Nonlinear Science and Numerical Simulation · doi:10.1016/j.cnsns.2020.105586 · Cited by 24 · see citing works

BRD4 modulates vulnerability of triple-negative breast cancer to targeting of integrin-dependent signaling pathways

Zhang, Y., Xu, B., Shi, J., Li, J., Lu, X., Xu, L., Yang, H. L., Hamad, N., Wang, C., Napier, D. L., et al. (2020) · Cellular Oncology · doi:10.1007/s13402-020-00537-1 · Cited by 24 · see citing works

What do cellular responses to acidity tell us about cancer?

Błaszczak, W., & Swietach, P. (2021) · Cancer and Metastasis Reviews · doi:10.1007/s10555-021-10005-3 · Cited by 23 · see citing works

The interplay of DNA damage, epigenetics and tumour heterogeneity in driving cancer cell fitness

Rouault, C. D., Charafe‐Jauffret, E., & Ginestier, C. (2025) · Nature Communications · doi:10.1038/s41467-025-64445-4 · Cited by 22 · see citing works

Validation of a non-oncogene encoded vulnerability to exportin 1 inhibition in pediatric renal tumors

Coutinho, D. F., Mundi, P. S., Marks, L. J., Burke, C., Ortiz, M. V., Diolaiti, D., Bird, L., Vallance, K., Ibáñez, G., You, D., et al. (2022) · Med · doi:10.1016/j.medj.2022.09.002 · Cited by 22 · see citing works

Spatiotemporal Profiling Defines Persistence and Resistance Dynamics during Targeted Treatment of Melanoma

Rubinstein, J. C., Domanskyi, S., Sheridan, T., Sanderson, B. J., Park, S., Kaster, J., Li, H., Anczuków, O., Herlyn, M., & Chuang, J. H. (2024) · Cancer Research · doi:10.1158/0008-5472.can-24-0690 · Cited by 21 · see citing works

Single-cell chromatin accessibility profiling of acute myeloid leukemia reveals heterogeneous lineage composition upon therapy-resistance

Fan, H., Wang, F., Zeng, A. G. X., Murison, A., Tomczak, K. J., Hao, D., Jelloul, F. Z., Wang, B., Barrodia, P., Liang, S., et al. (2023) · Communications Biology · doi:10.1038/s42003-023-05120-6 · Cited by 21 · see citing works

Single-cell evaluation reveals shifts in the tumor-immune niches that shape and maintain aggressive lesions in the breast

Sinha, V. C., Rinkenbaugh, A. L., Xu, M., Zhou, X., Zhang, X., Jeter-Jones, S. L., Shao, J., Qi, Y., Zebala, J. A., Maeda, D. Y., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25240-z · Cited by 21 · see citing works

Dynamical hallmarks of cancer: Phenotypic switching in melanoma and epithelial-mesenchymal plasticity

Jain, P., Pillai, M., Duddu, A. S., Somarelli, J. A., Goyal, Y., & Jolly, M. K. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.09.007 · Cited by 22 · see citing works

Systems biology approaches to measure and model phenotypic heterogeneity in cancer

Meyer, A. S., & Heiser, L. M. (2019) · Current Opinion in Systems Biology · doi:10.1016/j.coisb.2019.09.002 · Cited by 20 · see citing works

Epigenome erosion and SOX10 drive neural crest phenotypic mimicry in triple-negative breast cancer

Saunus, J., de Luca, X. D., Northwood, K. S., Raghavendra, A., Hasson, A., Reed, A. M., Lim, M., Lal, S., Vargas, A., Kutasovic, J., et al. (2022) · npj Breast Cancer · doi:10.1038/s41523-022-00425-x · Cited by 18 · see citing works

mTOR signaling regulates gastric epithelial progenitor homeostasis and gastric tumorigenesis via MEK1-ERKs and BMP-Smad1 pathways

Li, K., Wu, H., Wang, A., Charron, J., Mishina, Y. M., Habib, S. L., Liu, H., & Li, B. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109069 · Cited by 19 · see citing works

Adaptive chromatin remodeling and transcriptional changes of the functional kinome in tumor cells in response to targeted kinase inhibition

East, M. P., & Johnson, G. L. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.101525 · Cited by 20 · see citing works

Modeling differentiation-state transitions linked to therapeutic escape in triple-negative breast cancer

Chapman, M. P., Risom, T., Aswani, A. J., Langer, E. M., Sears, R. C., & Tomlin, C. J. (2019) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1006840 · Cited by 18 · see citing works

BET protein inhibition evidently enhances sensitivity to PI3K/mTOR dual inhibition in intrahepatic cholangiocarcinoma

Miao, X., Liu, C., Jiang, Y., Wang, Y., Kong, D., Wu, Z., Wang, X., Tian, R. L., Yu, X., Zhu, X., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-04305-3 · Cited by 18 · see citing works

Fibrin Stiffness Regulates Phenotypic Plasticity of Metastatic Breast Cancer Cells

Heilala, M., Lehtonen, A. J., Arasalo, O., Peura, A., Pokki, J., Ikkala, O. T., Nonappa, N., Klefström, J. T., & Munne, P. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202301137 · Cited by 17 · see citing works

Persisting cancer cells are different from bacterial persisters

Decollogny, M., & Rottenberg, S. (2024) · Trends in cancer · doi:10.1016/j.trecan.2024.02.002 · Cited by 17 · see citing works

Interaction between MED12 and ΔNp63 activates basal identity in pancreatic ductal adenocarcinoma

Maia-Silva, D., Cunniff, P. J., Schier, A. C., Skopelitis, D. S., Trousdell, M. C., Moresco, P., Gao, Y., Kechejian, V., He, X., Sahin, Y., et al. (2024) · Nature Genetics · doi:10.1038/s41588-024-01790-y · Cited by 17 · see citing works

Targeting the Heterogeneous Genomic Landscape in Triple-Negative Breast Cancer through Inhibitors of the Transcriptional Machinery

van der Noord, V. E., van de Water, B., & Dévédec, S. E. L. (2022) · Cancers · doi:10.3390/cancers14184353 · Cited by 17 · see citing works

Genome-wide DNA methylation signatures to predict pathologic complete response from combined neoadjuvant chemotherapy with bevacizumab in breast cancer

Hsu, P.-C., Kadlubar, S. A., Siegel, E. R., Rogers, L. J., Todorova, V. K., Su, L. J., & Makhoul, I. (2020) · PLoS ONE · doi:10.1371/journal.pone.0230248 · Cited by 16 · see citing works

BET Inhibition Induces Vulnerability to MCL1 Targeting Through Upregulation of Fatty Acid Synthesis Pathway in Breast Cancer

Yan, G., Luna, A., Wang, H., Bozorgui, B., Li, X., Sanchez, M., Dereli, Z., Kahraman, N., Kara, G., Chen, X., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2022.111304 · Cited by 17 · see citing works

Ex vivo assessment of targeted therapies in a rare metastatic epithelial–myoepithelial carcinoma

Mäkelä, R., Arjonen, A., Rahmanto, A. S., Härmä, V., Lehtiö, J., Kuopio, T., Helleday, T., Sangfelt, O., Kononen, J., & Rantala, J. (2020) · Neoplasia · doi:10.1016/j.neo.2020.06.007 · Cited by 16 · see citing works

Secondary resistance to anti-EGFR therapy by transcriptional reprogramming in patient-derived colorectal cancer models

Vangala, D., Ladigan, S., Liffers, S. T., Noseir, S., Maghnouj, A., Götze, T.-M., Verdoodt, B., Klein‐Scory, S., Godfrey, L., Zowada, M. K., et al. (2021) · Genome Medicine · doi:10.1186/s13073-021-00926-7 · Cited by 15 · see citing works

An inflamed tumor cell subpopulation promotes chemotherapy resistance in triple negative breast cancer

Jacobo, M. J., Donnella, H. J., Sobti, S., Kaushik, S., Goga, A., & Bandyopadhyay, S. (2024) · Scientific Reports · doi:10.1038/s41598-024-53999-w · Cited by 13 · see citing works

The epigenome and the many facets of cancer drug tolerance

Moore, P. C., Henderson, K. W., & Classon, M. (2023) · Advances in cancer research · doi:10.1016/bs.acr.2022.12.002 · Cited by 14 · see citing works

Epigenetic adaptations in drug-tolerant tumor cells

Mani, N., Daiya, A., Chowdhury, R., Mukherjee, S., & Chowdhury, S. (2023) · Advances in cancer research · doi:10.1016/bs.acr.2022.12.006 · Cited by 13 · see citing works

A high-throughput drug screen reveals means to differentiate triple-negative breast cancer

Vulin, M., Jehanno, C., Sethi, A., Correia, A. L., Obradović, M. M. S., Couto, J. P., Coissieux, M., Diepenbruck, M., Preca, B., Volkmann, K., et al. (2022) · Oncogene · doi:10.1038/s41388-022-02429-0 · Cited by 13 · see citing works

Cell-state transitions and density-dependent interactions together explain the dynamics of spontaneous epithelial-mesenchymal heterogeneity

Jain, P., Kizhuttil, R., Nair, M. B., Bhatia, S., Thompson, E. W., George, J. T., & Jolly, M. K. (2024) · iScience · doi:10.1016/j.isci.2024.110310 · Cited by 12 · see citing works

Cotargeting BET proteins overcomes resistance arising from PI3K / mTOR blockade‐induced protumorigenic senescence in colorectal cancer

Lee, H., Lee, S., & Cho, K. (2020) · International Journal of Cancer · doi:10.1002/ijc.33047 · Cited by 12 · see citing works

Stochastic population dynamics of cancer stemness and adaptive response to therapies

Jain, P., Duddu, A. S., & Jolly, M. K. (2022) · Essays in Biochemistry · doi:10.1042/ebc20220038 · Cited by 12 · see citing works

A phenotype-structured model to reproduce the avascular growth of a tumor and its interaction with the surrounding environment

Fiandaca, G., Bernardi, S., Scianna, M., & Delitala, M. E. (2021) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2021.110980 · Cited by 11 · see citing works

Modeling differentiation-state transitions linked to therapeutic escape in triple-negative breast cancer

Chapman, M. P., Risom, T., Aswani, A. J., Langer, E. M., Sears, R. C., & Tomlin, C. J. (2019) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1006840 · Cited by 18 · see citing works

Abstract LB-222: Differentiation state heterogeneity in breast cancer and its role in therapeutic response

Risom, T., Rantala, J., Langer, E. M., Wang, N., Heiser, L. M., Troxell, M. L., Gray, J. W., & Sears, R. C. (2014) · Cancer Research · doi:10.1158/1538-7445.am2014-lb-222

Multimodal profiling unveils a reversible breast basal-like cell state in AKT-inhibitor resistant tumoursPreprint

Ratcliffe, C. D. H., Sparks, H., Boezio, G. L. M., Alexandrov, Y., Jenkins, R. P., Marois, A. L., Soro-Barrio, P., Moughari, F. A., Hulme, H., Lee, R. J., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.06.06.658331 · Cited by 1 · see citing works

Abstract B52: Overcoming phenotypic heterogeneity and plasticity in basal-like breast cancer through targeting adaptive pathway use

Risom, T., Langer, E. M., Rantala, J., Alvarez, M. J., Johnson-Camacho, K., Pelz, C., Wang, N., Spellman, P. T., Califano, A., Gray, J. W., et al. (2016) · Molecular Cancer Research · doi:10.1158/1557-3125.advbc15-b52

TUMOR PLASTICITY AND PHENOTYPIC SWITCHING AS DRIVERS OF THERAPEUTIC RESISTANCE IN BREAST CANCER

Agarwal*1, P. (2026) · Zenodo (CERN European Organization for Nuclear Research) · doi:10.5281/zenodo.22211814